絞り込み

16641

広告

Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.

著者 Li S , Meng XY , Maman STD , Xiao YN , Li S
Biomed Res Int.2018 ; 2018():9057823.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (593view , 0users)

Full Text Sources

Medical

Miscellaneous

Refractory and relapsed multiple myeloma (RRMM) remains a clinical challenge. We compared the progression-free survival (PFS) of RRMM patients treated with lenalidomide and low dose dexamethasone plus elotuzumab or carfilzomib (ELD vs. CLD), using reconstructed individual patient data (IPD) based on two published trials reports.
PMID: 30643823 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード